Concepedia

Shalini Subramaniam

SS

Statistics

Publications

10

Citations

1.6K

H-Index

10

Active since

2021

Affiliations

Eastern Health(Current)

Monash University

The University of Sydney

National Health and Medical Research Council

Peter MacCallum Cancer Centre

Shalini Subramaniam is an author at Eastern Health specializing in medicine, metastatic castration-resistant prostate cancer, and prostate cancer.

ORCID

Publications per year

2021–2025

10

Publications

10

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet · 2021 · 1.1K citations

, , +12

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet Oncology · 2023 · 199 citations

, , +16

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Louise Emmett, Shalini Subramaniam, Megan Crumbaker et al. · The Lancet Oncology · 2024 · 155 citations

, , +12

ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration‐resistant prostate cancer treated with enzalutamide (ANZUP 1901)

Louise Emmett, Shalini Subramaniam, Anthony M. Joshua et al. · British Journal of Urology · 2021 · 46 citations

, , +17

Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial

Edmond M. Kwan, Sarah W.S. Ng, Sofie H. Tolmeijer et al. · Nature Medicine · 2025 · 32 citations

, , +17

1–5 of 10